Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab With or Without Olaparib in First-Line Platinum-Ineligible Stage IV Urothelial Cancer
NCT03459846Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of olaparib in urothelial carcinoma (UC), sponsored by AstraZeneca. Started Mar 2018; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03459846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459846.